EuroPCR 2019 News: BOWIE Study

I’ve always enjoyed attending the annual EuroPCR conference as it is a fantastic way to learn the latest data and hear about exciting new technologies and approaches in interventional cardiology. At this year’s EuroPCR, we had the privilege of seeing new data presented on the HeartFlow Planner – a real-time, non-invasive interactive planning tool (still investigational at present).

The BOWIE (Benefits of Obtaining information for planning With non-invasive FFRCT prior to Invasive Evaluation) study was presented by Eric Van Belle, M.D., Ph.D, of the Lille Heart & Lung Institute as a late-breaking trial. BOWIE is a retrospective study that included 101 patients with coronary artery disease (CAD) and also who had undergone CTA, HeartFlow Analysis, and invasive coronary angiography. Three interventional cardiologists independently reviewed the diagnostic invasive angiogram for each patient and provided a treatment recommendation based on that alone. The same three interventional cardiologists then reviewed each patient’s HeartFlow Analysis and used the investigational HeartFlow Planner to virtually explore different treatment scenarios and provide a treatment recommendation based on that alone. The study then compared the two independent treatment recommendations.

The study found that use of the investigational HeartFlow Planner:

The conclusion of the investigators was: “The results emphasize the potential benefit of the use of a real-time interactive FFRCT planner pre-angiography to help inform revascularization decision making, optimize completeness of revascularization, and streamline resource utilization among CAD patients.”

BOWIE presentation PCR 2019

The investigational HeartFlow Planner is an interactive tool that enables interventional cardiologists and heart teams to modify vessels virtually and view the resulting FFRCT changes in real time. This tool allows the non-invasive study of treatment scenarios prior to an invasive procedure. The HeartFlow Planner is currently not available for commercial use and is under review with the U.S. Food and Drug Administration (FDA).

Download PDF

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.